February 2, 2026
Stage of Investment: Multi-stage / Growth & late venture / life sciences. They invest at all stages—incubation, early-stage, growth, pre-IPO, etc.
Headquarter: Primarily in the San Francisco Bay Area (Larkspur / near SF), with additional offices in Los Angeles and New York City
AUM: Over US$3.5 billion as of mid-2024
Foresite Capital was established in 2011 by Jim Tananbaum, Foresite seeks out companies that address significant unmet needs in healthcare, particularly at the intersection of biotechnology, big data, and healthcare delivery. Their investment model is thesis-driven, data-science informed, with a deeply technical investment team (MDs, PhDs, analysts). They do full lifecycle investing which helps companies from early stages, through growth phases, to IPO or acquisition. They emphasize deep collaboration and operational / scientific support, not just capital. In June 2024, they closed Fund VI with $900 million in capital commitments. That makes it their latest primary fund.
Approximately US$3.5 billion+ managed as of mid-2024
Sectors: Health & Life Sciences broadly, including therapeutics, biotech, diagnostic / life science tools, healthcare delivery, infrastructure, health data.
Thematic Emphases: Tech-bio convergence; precision therapeutics; using big data and biology; investing at the intersection of biotech and technology; transforming how healthcare is discovered, delivered, and scaled. All stages from incubation / early-stage through growth / pre-IPO / late rounds.
Here are some of the companies they have invested in, across different categories:
These are just a sample; they have many others across therapeutics, diagnostics, and bioinformatics.
Jim Tananbaum, MD — Founder & CEO, Foresite Capital
Dr. Jim Tananbaum unites deep scientific training, entrepreneurial experience, and visionary investing as the Founder & CEO of Foresite Capital, guiding the firm to back transformational healthcare companies across therapeutics, diagnostics, devices, and services.
As an undergraduate at Yale, he earned a B.S. and B.S.E.E. in Applied Mathematics and Electrical Engineering / Computer Science; he then went on to complete both an M.D. and an MBA from Harvard, and trained in the Harvard-MIT Health Sciences & Technology (HST) program. Early in his career, he co-founded and served as CEO of GelTex Pharmaceuticals (later acquired) and later founded Theravance. Over 30 years of investing and building in healthcare, he has been a thought partner to companies like 10x Genomics, Amerigroup, and Jazz Pharmaceuticals. He has been recognized repeatedly, including being a multiple-time honoree on Forbes’ Midas List.
